β-Hydroxy-β-methylbutyrate (HMB) is a leucine metabolite available in calcium salt (CaHMB) and free acid forms as a sports nutrition ergogenic aid. HMB has also been used to support muscle health in the elderly and other populations needing to maintain muscle mass. Several human studies have reported safety data for CaHMB, and rodent sub-chronic toxicity studies have been conducted; however, there are no published genotoxicity studies for HMB. Therefore, three studies (a bacterial reverse mutation test, an in vitro mammalian chromosomal aberration test, and an in vivo mammalian cell micronucleus test) were performed. In the Ames test, no changes in revertant colonies or background were noted with CaHMB concentrations up to 5000 μg per plate, either with or without metabolic activation in five bacterial strains. In the chromosomal aberration test, the number of aberrations associated with up to 2.5 mM CaHMB (long-term) or 10.0 mM (short-term) were similar to those observed for negative controls (< 5%), and no polyploidy was observed. Lastly, in the mammalian micronucleus test, no changes in immature erythrocyte or micronuclei frequencies were observed in animals treated with up to 2000 mg·kg −1 body weight CaHMB. In conclusion, CaHMB was determined to have no genotoxic effects.
Introduction
β-Hydroxy-β-methylbutyrate (HMB) is a naturally occurring metabolite of leucine, an essential amino acid (Nissen and Abumrad, 1997) . Typically, about 5% of leucine is oxidized to HMB, but due to the ability of HMB to increase protein synthesis and reduce protein degradation (Wilkinson et al., 2013) , it has been widely used as a nutritional supplement. Calcium HMB (CaHMB), the calcium salt of HMB, has been shown to enhance muscular strength, size, and recovery from exercise. These and other beneficial effects on muscle health have been demonstrated in young (Gallagher et al., 2000a; Jówko et al., 2001) , elderly (Baier et al., 2009) , athletic (Portal et al., 2010) , and clinical (Clark et al., 2000; Eubanks May et al., 2002) populations.
CaHMB has been commercially available and used safely by humans for over 20 years. Further, a critical analysis of HMB conducted by the International Society of Sports Nutritionists concluded that chronic consumption of HMB was safe for both young and old populations (Wilson et al., 2013) . However, relatively few formal safety studies have been conducted with HMB. A 90-day rodent toxicity study established no-observed-adverse-effect-levels of 3.49 and 4.16 g·kg BW −1 ·d −1 in male and female rats, respectively (Baxter et al., 2005) .
Based on the United States Food and Drug Administrationrecommended body surface area correction factors, these levels translate to ∼0.5 g·kg BW −1 ·d −1 in humans. This corresponds to > 30 g/d for a 70-kg person, which is more than 10 times the recommended dose.
In humans, consumption of up to 6 g of CaHMB per day did not induce any alterations in renal function, hepatic function, or hematology (Gallagher et al., 2000b) . Though these data and the history of safe CaHMB use are convincing, some aspects of the safety profile of CaHMB have not been published to date. Thus, a battery of three genotoxicity tests was conducted to examine the potential of CaHMB to induce several types of genetic damage (i.e., mutations, chromosomal abnormalities, and/or mitotic dysfunction), as recommended by FDA guidance (Office of Food Additive Safety U.S. Food and Drug Administration, 2007).
Materials and methods

Test article
The CaHMB used for these studies was manufactured by TSI (China) Co., Ltd. (Shanghai, China). The lot number used for the current studies was 17050103. This lot was determined to have 80.6% HMB by highperformance liquid chromatography analysis; this corresponds to 102.3% CaHMB as listed on the certificate of analysis.
Testing laboratory
All of the experiments described herein were conducted by the Japan Food Research Laboratories (Tokyo, Japan), which are certified according to ISO9001.
Bacterial reverse mutation test
A bacterial reverse mutation study (Ames test) was conducted according to Iyakushin No. 1604 (Ministry of Health and Welfare, November 1, 1999) and Yakushokushinsahatsu No. 0920-2 (Ministry of Health, Labour, and Welfare, September 20, 2012) ; these guidelines are comparable to the OECD Test No. 471 guidelines (OECD, 1997a) . Four strains of Salmonella typhimurium (TA98, TA100, TA1535, and TA1537) and one strain of Escherichia coli (WP2uvrA) were used for the test. The test strains were obtained from the Japan Industrial Safety and Health Association Japan Bioassay Research Center.
CaHMB was suspended in dimethylsulfoxide (DMSO, Dojindo Laboratories, Kumamoto, Japan) by ultrasonication and then serially diluted with DMSO to the test concentrations (5000, 2500, 1250, 625, and 313 μg/plate). Studies were conducted using the pre-incubation method, both with (+S9) and without metabolic activation (-S9) with a mammalian microsome enzyme activation mixture (S9, Kikkoman Biochemifa Company, Tokyo, Japan). Negative control plates were treated with DMSO. Positive control plates were treated with the following controls: For -S9 plates, 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide (AF-2) (Wako Pure Chemical Industries, Osaka, Japan) in DMSO for TA98 (0.1 μg/plate), TA100 (0.01 μg/plate), and WP2uvrA (0.01 μg/plate); 0.5 μg/plate sodium azide (Wako) in water (Otsuka Pharmaceutical Factory, Tokyo, Japan) for TA1535, and 80 μg/plate 9-aminoacridine hydrochloride monohydrate (Tokyo Chemical Industry, Tokyo, Japan) in DMSO for TA1537. For + S9 plates, 2-aminoanthracene (Wako) in DMSO was added at the following doses: TA98, 0.5 μg/plate; TA100, 1 μg/plate; TA1535, 2 μg/plate; TA1537 2 μg/plate; and WP2uvrA, 10 μg/plate.
A 0.1 mL aliquot of CaHMB test solution, DMSO (negative control), or positive control was used for each assay. Next, 0.5 mL S9 mix (+S9) or 0.5 mL of sodium phosphate buffer, pH 7.4 (-S9), and 0.1 mL of the bacterial suspensions were mixed in a test tube and incubated at 37°C for 20 min. After incubation, 2 mL of top agar (Bacto™ Difco™ agar, BD, Franklin, NJ, USA) were added to each tube, and the mixture was then poured onto minimal glucose agar plates (Vitalmedia MT-S, Kyokuto Pharmaceutical Industrial Co., Tokyo, Japan). The plates were incubated for 48 h at 37°C in the dark, after which the number of revertant colonies per plate was counted. Three replicate plates were used for all conditions. A positive (mutagenic) result was defined as a mean number of revertant colonies in the test plate that was two or more times greater than the number of revertant colonies in the negative control plate (Hamada et al., 1994) .
In vitro mammalian chromosomal aberration test
The potential clastogenic activity of CaHMB was evaluated in chromosome aberration tests; these tests conducted in accordance with and Welfare, March 22, 1996) ; these guidelines are comparable to the OECD Test No. 473 guidelines (OECD, 1997b) .
Chinese Hamster Lung (CHL)/IU cells (DS Pharma Biomedical, Osaka, Japan) were used for all chromosomal aberration tests. CHL/IU cells were used to avoid potential interference from any background chromosomal aberrations in primary cells. For the short-term exposure test, cells were plated (4 × 10 3 cells/mL) in growth medium (Eagle's Minimum Essential Medium with 10% calf serum) and incubated for 3 days at 37°C and 5% CO 2 . Then, the medium was replaced with test media (Eagle's Minimum Essential Medium with 60 mg/L kanamycin and 10% calf serum) containing 0 (negative control), 2.5, 5, or 10 mM CaHMB and incubated for 6 h at 37°C and 5% CO 2 . Plates were prepared with (+S9) and without (-S9) metabolic activation with S9 solution for all dose levels. Benzo[a]pyrene (10 μg/mL; Sigma-Aldrich, St. Louis, MO, USA) was used as a positive control for the +S9 condition, and mitomycin C (0.05 μg/mL; Kyowa Hakko Kirin, Tokyo, Japan) was used as a positive control for the -S9 condition. After 6 h, the medium was replaced with test media, and the cells were incubated an additional 18 h. In the long-term exposure test, the cells were instead treated with 0 (negative control), 0.313, 0.625, 1.25, and 2.5 mM CaHMB in Eagle's Minimum Essential Medium with 60 mg/L kanamycin and 10% calf serum and incubated for 24 h at 37°C and 5% CO 2. Mitomycin C (0.02 μg/mL) was used as a positive control.
For both the short-and long-term exposure tests, chromosome preparations were prepared after incubations. Colcemid (0.1 μg/mL) was added to the medium two hours before the end of incubation. After incubation, the cells were harvested by trypsinization, swollen by hypotonic treatment with 0.075 mol/L potassium chloride solution, and fixed with Carnoy's fixative (3:1 methanol:acetic acid, v:v). The fixed cells were dropped onto glass slides, air-dried, and stained with 1.5% Giemsa stain.
All slides were coded and blindly evaluated for chromosome aberrations at 600× magnification. One hundred metaphase cells per plate were observed; the number of cells with chromosomal aberrations and the number of cells for each type of aberration were recorded. Chromosome aberrations were classified into the following structural aberrations: chromatid break, chromatid exchange, chromosome break, chromosome exchange, and other (e.g. fragmentation, multiple aberrations). A positive test was defined as ≥10% frequency of cells with chromosomal aberrations. Cells were also examined for polyploidy (greater than 38 chromosomes).
In vivo mammalian cell micronucleus test
This test was conducted to identify any clastogenic effects of CaHMB on murine bone marrow cells. This test was conducted in accordance with the OECD Guidelines for the Testing of Chemicals 474 (OECD, 2016) .
Eight-week-old male ICR mice were purchased from Japan SLC, Inc. (Shizuoka, Japan). Mice were housed in plastic cages under standard conditions (20-26°C, 30-80% relative humidity, 12/12 h light/dark cycle) and fed standard mouse chow (CRF-1, Oriental Yeast Co., Tokyo, Japan) and water ad libitum.
Five groups of mice (n = 6 per group) were used for the micronucleus test as follows: 500 mg/kg CaHMB, 1000 mg/kg CaHMB, 2000 mg/kg HMB, positive control, and negative control. Mice were randomly allocated to groups to minimize variation in body weight. The appropriate doses of CaHMB and appropriate bone-marrow harvest time were established in preliminary tests (data not shown). The CaHMB test solutions were prepared by dissolving CaHMB in sterile water at 50, 100, and 200 mg/mL. Cyclophosphamide monohydrate in isotonic sodium chloride (5 mg/mL) was used as a positive control. CaHMB and the negative control, water, were administered at 10 mL/ kg with a stomach tube, while the positive control was administered intraperitoneally (10 mL/kg).
At 24 (positive control) or 72 (all other groups) hours post-administration, mice were sacrificed by cervical dislocation, and the femoral bone marrow was harvested by flushing with fetal bovine serum. Bone marrow cells were centrifuged at 200×g for 5 min), then the supernatant was discarded and the cells were resuspended in the remaining serum. The bone marrow preparations were smeared onto glass slides, fixed with methanol, and stained with a 1:2 mixture of acridine orange
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Regulatory Toxicology and Pharmacology 100 (2018) [68] [69] [70] [71] and M/15 phosphate-buffered saline, pH 6.4. The slides were coded for blind analysis and examined by fluorescence microscopy. The frequency of immature erythrocytes and the frequency of micronuclei were calculated using the following equations:
= ×
Frequency of immature erythrocytes (%) mmature erythrocytes 100 Total erythrocytes (minimum 500 cells)
Frequency of micronuclei (%) Micronucleated immature erythrocytes 100 Total immature erythrocytes (minimum 4000 cells)
The frequencies of immature erythrocytes in the CaHMB groups were analyzed with the Kruskal-Wallis rank test with the significance level set to p < 0.05. The average frequencies of immature erythrocytes in the positive and negative control groups were analyzed with the Mann Whitney-U test with the significance level set to p < 0.05. The frequencies of micronuclei in the CaHMB and positive control groups were compared to the frequency of micronuclei in the negative control group using a binomial test. The significant level was set to p < 0.05, which was Bonferroni-corrected for multiple testing. The Cochran-Armitage trend test with a significance level of p < 0.05 was used to detect dose-dependency. A positive test was defined as a statistically significant, dose-dependent increase in the frequency of micronuclei in a test group compared with the negative control.
Results
Bacterial reverse mutation test
The bacterial reverse mutation test results are shown in Table 1 . No changes in revertant colony counts were observed when comparing CaHMB-treated plates with negative control plates in any of the strains tested; this was true both in the presence and absence of metabolic activation. The plate counts for all levels of CaHMB tested were similar to those observed in the negative control plates and were far below the two-fold threshold that would justify further analysis. Positive controls resulted in a marked increase in revertant colonies compared with negative controls.
In vitro mammalian chromosomal aberration test
The results of the chromosomal aberration test are shown in Table 2 . No cytotoxicity was observed with any of the CaHMB concentrations tested (data not shown). The frequencies of cells with structural aberrations were less than 5% in both the negative control and CaHMB-treated samples, while marked induction of chromosome aberrations was observed in the positive control samples. No polyploidy was observed in any of the treatment conditions.
In vivo mammalian micronucleus test
No abnormalities or changes in body weight were observed in any of In the absence of metabolic activation (-S9) 0 (NC) 20.3 ± 5.7 83.0 ± 10.4 15.3 ± 3.8 11.7 ± 1.5 19.0 ± 4.4 313 14.0 ± 3.0 85.7 ± 12.0 12.0 ± 6.0 11.7 ± 3.5 23.0 ± 5.6 625 16.3 ± 4.0 82.7 ± 9.1 10.3 ± 4.2 6.0 ± 2.6 15.3 ± 6.1 1250 18.7 ± 3.5 85.3 ± 7.2 14.3 ± 4.0 12.0 ± 2.6 19.7 ± 1.2 2500 18.0 ± 3.5 81.3 ± 12.3 8.0 ± 4.0 12.3 ± 1.5 19.3 ± 7.0 5000 15.3 ± 3.5 85.0 ± 7.0 7.3 ± 6.1 9.0 ± 3.0 16.3 ± 4.0 PC 293.3 ± 29.4 334.3 ± 5.9 603.3 ± 51.5 172.7 ± 36.7 137.3 ± 14.5 In the presence of metabolic activation (-S9) 0 (NC) 15.3 ± 3.5 95.0 ± 19.1 12.7 ± 3.8 9.0 ± 3.0 32.0 ± 7.2 313 27.0 ± 4.6 80.0 ± 7.0 11.7 ± 1.2 29.3 ± 1.5 22.7 ± 2.9 625 21.0 ± 4.6 96.7 ± 2.5 15.7 ± 3.1 30.0 ± 8.5 29.3 ± 6.4 1250 23.7 ± 3.2 100.3 ± 1.2 13.7 ± 5.5 37.3 ± 5.5 20.7 ± 6.1 2500 28.3 ± 2.5 92.0 ± 3.6 11.0 ± 1.0 39.7 ± 3.8 29.7 ± 3.2 5000 25.7 ± 5.5 98.7 ± 11.9 12.3 ± 0. Data are presented as the mean number of revertant colonies ± SD (n = 3 per condition). a Treatments were 0 (NC) negative control, 313, 625, 1250, 2500, and 5000 μg calcium β-hydroxy β-methylbutyrate in dimethylsulfoxide/plate. The positive control (PC) treatments for the -S9 plates were 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide (AF-2) in DMSO for TA98 (0.1 μg/plate), TA100 (0.01 μg/plate), and WP2uvrA (0.01 μg/plate); 0.5 μg/plate sodium azide in water for TA1535, and 80 μg/plate 9-aminoacridine hydrochloride monohydrate in DMSO for TA1537. For + S9 plates, the PC was 2-aminoanthracene in DMSO at 0.5 (TA98), 1 (TA100), 2 (TA1535, TA1537), or 10 (WP2uvrA) μg/plate. Table 3 . The frequency of immature erythrocytes was significantly lower (p < 0.05) in the positive control group relative to the negative control group, but no significant differences in immature erythrocyte frequency were observed between the CaHMB groups and the negative control group. A significant increase (p < 0.0125) in micronuclei frequency was observed in the positive control group relative to the negative control group, but no significant differences in micronuclei frequency were observed between the CaHMB and negative control groups.
Discussion
The lack of increase in revertant colonies in the bacterial reverse mutation test support that CaHMB is not mutagenic. However, it is important to consider that while a positive bacterial reverse mutation test result predicts carcinogenicity in rodents (Mortelmans and Zeiger, 2000) , the prokaryotic Ames assessment does not directly assess mutagenicity in mammals. The results of chromosomal aberration test show that CaHMB does not induce mammalian chromosomal alterations in the tested system. The in vivo mouse micronucleus test identified no differences in micronuclei frequency in CaHMB treated mice, indicating that CaHMB does not exert clastogenic effects or impact mitotic processes in murine bone marrow cells.
No published genotoxicity studies of CaHMB exist, but other safety and toxicity studies demonstrate a good safety profile for CaHMB. In a previous 90-day rat toxicity study (Baxter et al., 2005) , no CaHMBrelated adverse effects were observed on clinical signs, body weight, feed consumption, clinical chemistry, hematology, organ weights, or tissue observations with CaHMB consumption at up to 5% by weight in the feed. A 90-day rat toxicity study of the free acid form of HMB (HMBFA) (Fuller et al., 2014) yielded similar results; there were no toxicologically relevant observations at HMBFA consumption levels of up to 4% (the highest level tested) in the feed. These rodent safety studies indicate the safety of HMB consumption at doses at least 5-10 times higher than those recommended for human use. Accordingly, CaHMB also has a strong safety profile in humans. Consumption of CaHMB in doses up to 6 g per day was not associated with any alterations in renal function, hepatic function, or hematology (Gallagher et al., 2000b) , and a critical analysis of the literature concluded that HMB consumption was safe for both young and old populations (Wilson et al., 2013) .
In conclusion, the results of these examinations of CaHMB do not indicate any genotoxicity concerns. When considered alongside the existing body of evidence, these findings further support the safety of dietary consumption of CaHMB. Data are presented as the mean frequency ± SD (n = 6/group). *p < 0.0125 compared to 0 (NC). a Treatments were 0 (NC) negative control, 500, 1000, or 2000 mg/kg body weight calcium β-hydroxy β-methylbutyrate in sterile water. The positive control (PC) was 50 mg/kg bodyweight cyclophosphamide in isotonic sodium chloride solution.
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